| 956 |
occurrence |
viral budding from plasma membrane
(GO:0046761)
|
|
2193: Influenza A Virus (IAV) budding
|
| 908 |
occurrence |
viral entry into host cell
(GO:0046718)
|
viral genome
(GO:0019015)
|
1738: SARS-CoV-2 cell entry
|
| 909 |
occurrence |
viral entry into host cell
(GO:0046718)
|
viral protein
(PR:000036197)
|
1738: SARS-CoV-2 cell entry
|
| 951 |
occurrence |
viral mRNA export from host cell nucleus
(GO:0046784)
|
|
2192: Influenza A Virus production increased
|
| 824 |
increased |
viral release from host cell
(GO:0019076)
|
|
1939: Viral infection and host-to-host transmission, proliferated
|
| 760 |
increased |
viral RNA genome packaging
(GO:0019074)
|
|
None
|
| 761 |
increased |
viral RNA genome packaging
(GO:0019074)
|
viral assembly compartment
(GO:0072516)
|
1847: Increased SARS-CoV-2 production
|
| 755 |
increased |
viral RNA genome replication
(GO:0039694)
|
|
None
|
| 756 |
increased |
viral RNA genome replication
(GO:0039694)
|
viral RNA-directed RNA polymerase complex
(GO:0031381)
|
1847: Increased SARS-CoV-2 production
|
| 763 |
increased |
viral translation
(GO:0019081)
|
ssRNA viral genome
(GO:0019024)
|
1847: Increased SARS-CoV-2 production
|
| 954 |
occurrence |
virus induced gene silencing
(GO:0009616)
|
|
2180: Immune mechanisms antagonized by viral proteins
|
| 952 |
occurrence |
virus maturation
(GO:0019075)
|
|
2192: Influenza A Virus production increased
|
| 810 |
functional change |
vision trait
(VT:0002090)
|
eye
(UBERON:0000970)
|
1643: Altered, Visual function
|
| 591 |
abnormal |
vitamin K metabolic process
(GO:0042373)
|
vitamin K
(CHEBI:28384)
|
1134: Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone
|
| 985 |
disrupted |
voltage-gated sodium channel activity
(GO:0005248)
|
|
1353: Binding to voltage-gated sodium channel
|
| 31 |
decreased |
weight loss
(MP:0001263)
|
|
None
|
| 597 |
decreased |
wellness/fitness trait
(VT:1000152)
|
|
1135: Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
|
| 725 |
increased |
Wnt protein secretion
(GO:0061355)
|
protein-serine O-palmitoleoyltransferase porcupine
(PR:000030936)
|
1754: Increase, porcupine-induced Wnt secretion and Wnt signaling activation
|
| 97 |
abnormal |
Wnt signaling pathway
(GO:0016055)
|
Wnt signalosome
(GO:1990909)
|
310: Alteration, Wnt pathway
|
| 581 |
abnormal |
wound healing
(GO:0042060)
|
|
1130: Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
|
| 1085 |
increased |
wounding
(MP:0013027)
|
Nose
(FMA:46472)
|
2312: Increased, nasal lesions
|